4142:TPE
Adimmune Corp
NT$ 16,15
arrow_downward
-0,62%(-0,10) 1D
18 de nov., 13:30:02 GMT+8 · TWD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 4142…
Abrir
NT$ 16,35
Alta
NT$ 16,55
Baixa
NT$ 16,00
Valor de mercado
6,94 bi
Volume médio
1,09 mi
Volume
534,85 mil
Alto — 52 sem
NT$ 21,50
Baixo — 52 sem
NT$ 15,65
LPA
-NT$ 0,34
Ações em circulação
235,29 mi
Nº de funcionários
564
Abrir
NT$ 16,35
Alta
NT$ 16,55
Baixa
NT$ 16,00
Valor de mercado
6,94 bi
Volume médio
1,09 mi
Volume
534,85 mil
Alto — 52 sem
NT$ 21,50
Baixo — 52 sem
NT$ 15,65
LPA
-NT$ 0,34
Ações em circulação
235,29 mi
Nº de funcionários
564
Notícias
De fontes da web e parceiros de notícias
Invezz
·
há 37 minutos
UBS prevê S&P 500 subindo 12% em 2027, mas alerta para grandes riscos ligados à IA
www.tmgm.com
·
há 1 dia
Dow Jones Industrial Average recua com pane na NSA; em seguida, Nvidia supera as expectativas
Times Brasil | CNBC
·
há 17 horas
Dow Jones perde mais de 800 pontos, enquanto S&P 500 registra menor fechamento desde julho
marketscreener.com
·
há 22 minutos
S&P 500, Nasdaq open higher as Nvidia forecast eases AI jitters
Perfil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Sobre Adimmune Corp